

Vladimir Ponomarev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6759493/publications.pdf>

Version: 2024-02-01

70
papers

4,770
citations

136950

32
h-index

98798

67
g-index

72
all docs

72
docs citations

72
times ranked

6851
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial to the Special Issue Entitled "Imaging in Immunooncology", Molecular Imaging and Biology, 2022, 24, 177-180.	2.6	1
2	A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials, 2021, 269, 120630.	11.4	27
3	Applications of nuclear-based imaging in gene and cell therapy: Probe considerations. Molecular Therapy - Oncolytics, 2021, 20, 447-458.	4.4	13
4	Introducing a new reporter gene, membrane-anchored Cypridina luciferase, for multiplex bioluminescence imaging. Molecular Therapy - Oncolytics, 2021, 21, 15-22.	4.4	11
5	Imaging CAR T-cell kinetics in solid tumors: Translational implications. Molecular Therapy - Oncolytics, 2021, 22, 355-367.	4.4	20
6	Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective. Cytotherapy, 2021, 23, 757-773.	0.7	9
7	Predicting CAR-T cell Immunotherapy Success through ImmunoPET. Clinical Cancer Research, 2021, 27, 911-912.	7.0	6
8	Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy. Molecular Therapy - Oncolytics, 2020, 18, 382-395.	4.4	17
9	Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583, 127-132.	27.8	483
10	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood Cancer Discovery, 2020, 1, 146-154.	5.0	114
11	Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction. Journal of Nuclear Medicine, 2019, 60, 879-881.	5.0	11
12	Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunology Research, 2019, 7, 2013-2024.	3.4	37
13	PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	5.0	51
14	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Journal of Experimental Medicine, 2018, 215, 159-175.	8.5	121
15	Zoledronate Enhances the Cytotoxicity of Gamma Delta T Cell Immunotherapy in an Orthotopic Mouse Model of Osteolytic Osteosarcoma. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	1
16	Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes. Methods in Molecular Biology, 2018, 1790, 153-163.	0.9	5
17	Imaging T Cell Dynamics and Function Using PET and Human Nuclear Reporter Genes. Methods in Molecular Biology, 2018, 1790, 165-180.	0.9	4
18	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	5.0	36

#	ARTICLE	IF	CITATIONS
19	Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 41-54.	4.4	74
20	Advancing Immune and Cell-Based Therapies Through Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 379-384.	2.6	20
21	Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. <i>Cancer Medicine</i> , 2017, 6, 2164-2176.	2.8	9
22	Comparative Analysis of Human Nucleoside Kinase-Based Reporter Systems for PET Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 100-108.	2.6	17
23	Adoptive transfer of ex vivo expanded $\text{V}\alpha^9\text{V}\beta^2$ T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. <i>Cancer Letters</i> , 2017, 386, 141-150.	7.2	24
24	Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment. <i>International Journal of Oncology</i> , 2017, 50, 1191-1200.	3.3	46
25	Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. <i>Cancer Medicine</i> , 2016, 5, 534-545.	2.8	27
26	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. <i>American Journal of Pathology</i> , 2016, 186, 3131-3145.	3.8	28
27	Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. <i>Cancer Letters</i> , 2015, 357, 160-169.	7.2	42
28	Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1055-1060.	5.0	66
29	Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. <i>Nature Biotechnology</i> , 2015, 33, 1079-1086.	17.5	134
30	Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. <i>International Journal of Oncology</i> , 2014, 45, 532-540.	3.3	20
31	Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). <i>Anticancer Research</i> , 2014, 34, 7007-20.	1.1	3
32	Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. <i>Journal of Clinical Investigation</i> , 2013, 123, 2654-2662.	8.2	21
33	Mechanism of cell death mediated by a BF_2 -chelated tetraarylazadipyromethene photodynamic therapeutic: Dissection of the apoptotic pathway <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 130, 705-715.	5.1	36
34	Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin <i>in vivo</i> . <i>Journal of Bone and Mineral Research</i> , 2011, 26, 630-643.	2.8	19
35	<i>In vivo</i> bioluminescence tomography with a blocking-off finite-difference method and MRI/CT coregistration. <i>Medical Physics</i> , 2010, 37, 329-338.	3.0	70
36	A New Pyrimidine-Specific Reporter Gene: A Mutated Human Deoxycytidine Kinase Suitable for PET During Treatment with Acycloguanosine-Based Cytotoxic Drugs. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1395-1403.	5.0	59

#	ARTICLE	IF	CITATIONS
37	Vascular Endothelial Growth Factor-C Induces Lymphangitic Carcinomatosis, an Extremely Aggressive Form of Lung Metastases. <i>Cancer Research</i> , 2010, 70, 1814-1824.	0.9	36
38	Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 1998-2009.	7.0	32
39	Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 3451-3461.	7.0	68
40	Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2969-2980.	4.1	41
41	Nuclear Imaging of Cancer Cell Therapies. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1013-1016.	5.0	27
42	PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1273-1282.	6.4	15
43	Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. <i>Nature Biotechnology</i> , 2008, 26, 91-100.	17.5	108
44	A New Acycloguanosine-Specific Supermutant of Herpes Simplex Virus Type 1 Thymidine Kinase Suitable for PET Imaging and Suicide Gene Therapy for Potential Use in Patients Treated with Pyrimidine-Based Cytotoxic Drugs. <i>Journal of Nuclear Medicine</i> , 2008, 49, 713-720.	5.0	22
45	Imaging Transgene Activity <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 2878-2884.	0.9	15
46	Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein. <i>Acta Oncologica</i> , 2008, 47, 1211-1220.	1.8	12
47	Monitoring the Efficacy of Adoptively Transferred Prostate Cancer-Targeted Human T Lymphocytes with PET and Bioluminescence Imaging. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1162-1170.	5.0	84
48	Imaging Regulation of Endogenous Gene Expression Using Spliceosome-Mediated <i>Trans</i> -Splicing. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1035-1037.	5.0	2
49	Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2900-2908.	4.1	27
50	A Human-Derived Reporter Gene for Noninvasive Imaging in Humans: Mitochondrial Thymidine Kinase Type 2. <i>Journal of Nuclear Medicine</i> , 2007, 48, 819-826.	5.0	93
51	Human reporter genes: potential use in clinical studies. <i>Nuclear Medicine and Biology</i> , 2007, 34, 791-807.	0.6	110
52	T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. <i>Nature Medicine</i> , 2007, 13, 1440-1449.	30.7	265
53	Optical bioluminescence imaging of human ES cell progeny in the rodent CNS. <i>Journal of Neurochemistry</i> , 2007, 102, 2029-2039.	3.9	26
54	NF- κ B is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. <i>Blood</i> , 2006, 107, 3295-3302.	1.4	160

#	ARTICLE	IF	CITATIONS
55	Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10640-10645.	7.1	35
56	Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. Journal of Clinical Investigation, 2005, 115, 44-55.	8.2	606
57	Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice. Cancer Research, 2004, 64, 6101-6108.	0.9	179
58	PET-based reporter gene imaging. IEEE Engineering in Medicine and Biology Magazine, 2004, 23, 38-50.	0.8	4
59	A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 740-751.	6.4	266
60	In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method. Magnetic Resonance in Medicine, 2004, 52, 169-173.	3.0	8
61	Multimodality in Vivo Molecular-Genetic Imaging. Bioconjugate Chemistry, 2004, 15, 1376-1388.	3.6	104
62	Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nature Biotechnology, 2003, 21, 405-413.	17.5	224
63	Cytoplasmically Retargeted HSV1-tk/GFP Reporter Gene Mutants for Optimization of Noninvasive Molecular-Genetic Imaging. Neoplasia, 2003, 5, 245-254.	5.3	48
64	Development of a New Reporter Gene System-dsRed/Xanthine Phosphoribosyltransferase-Xanthine for Molecular Imaging of Processes Behind the Intact Blood-Brain Barrier. Molecular Imaging, 2003, 2, 153535002003031.	1.4	4
65	Development of a New Reporter Gene System-dsRed/Xanthine Phosphoribosyltransferase-Xanthine for Molecular Imaging of Processes Behind the Intact Blood-Brain Barrier. Molecular Imaging, 2003, 2, 93-112.	1.4	35
66	Imaging Expression of Cytosine Deaminase-Herpes Virus Thymidine Kinase Fusion Gene (CD/TK) Expression with [124I]FIAU and PET. Molecular Imaging, 2002, 1, 153535002002000.	1.4	12
67	Imaging Expression of Cytosine Deaminase-Herpes Virus Thymidine Kinase Fusion Gene (CD/TK) Expression with [124I]FIAU and PET. Molecular Imaging, 2002, 1, 36-42.	1.4	45
68	Imaging TCR-Dependent NFAT-Mediated T-Cell Activation with Positron Emission Tomography In Vivo. Neoplasia, 2001, 3, 480-488.	5.3	150
69	Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9300-9305.	7.1	223
70	Imaging Regulation of Endogenous Gene Expression in Living Subjects. , 0, , 239-257.		0